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Abstract
Achieving practice change can be challenging when guidelines shift from a selective 
risk-based strategy to a broader population health strategy, as occurred for hepatitis 
C (HCV) screening (2012-2013). We aimed to evaluate patient and provider barri-
ers that contributed to suboptimal HCV screening and linkage-to-care rates after 
implementation of an intervention to improve HCV screening and linkage-to-care 
processes in a large, public integrated healthcare system following the guidelines 
change. As part of a mixed-methods study, we collected data through patient sur-
veys (n = 159), focus groups (n = 9) and structured observation of providers and staff 
(n = 9). We used these findings to then inform domains for the second phase, which 
consisted of semi-structured interviews with patients across the screening-treat-
ment continuum (n = 24) and providers and staff at primary care and hepatology clin-
ics (n = 21). We transcribed and thematically analysed interviews using an integrated 
inductive and deductive framework. We identified lack of clarity about treatment 
cost, treatment complications and likelihood of cure as ongoing patient-level barriers 
to screening and linkage to care. Provider-level barriers included scepticism about 
establishing HCV screening as a quality metric given competing clinical priorities, 
particularly for patients with multiple comorbidities. However, most felt positively 
about adding HCV as a quality metric to enhance HCV screening and linkage to care. 
Provider engagement yielded suggestions for process improvements that resulted in 
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1  | BACKGROUND
Changes in recommendations for guideline-based care are common 
in the current era of rapidly changing scientific discovery. However, 
achieving practice change in response to shifting guidelines can be 
arduous, particularly in large, integrated healthcare systems.1 In 
2013, the US Preventive Services Task Force recommended one-
time screening for hepatitis C (HCV) infection for all adults born 
between 1945 and 1965, thereby simplifying screening from a risk-
based approach to a population-based strategy in this age group.2 
This recommendation coincided with the advent of direct-acting an-
tiviral (DAA) treatment that substantially increased treatment eligi-
bility, tolerability and effectiveness. Although a shift from risk-based 
to population-based screening may seem straightforward, it can be 
difficult to achieve because it requires providers to move from a 
paradigm of screening and treating a few patients to screening and 
treating many.
In response to the change in guidelines, Parkland Health and 
Hospital System (Parkland), Dallas County's safety-net health sys-
tem, developed a multi-level HCV screening process intervention to 
promote HCV screening and linkage to care (hereafter referred to 
as ‘the HCV intervention’). The HCV intervention comprised three 
parts. First, system-level changes included creation of an HCV regis-
try within the Epic electronic health record (EHR) with a best practice 
alert (BPA) highlighting the need for HCV screening among patients 
born between 1945 and 1965 who are HCV screen-naïve, a stream-
lined referral process, and expansion of the HCV Treatment Clinic 
that increased capacity fivefold. Second, hepatology and infectious 
disease specialists performed provider-level education through in-
clinic forums for primary care providers (PCPs) and staff. Finally, 
we conducted patient-level telephone outreach and navigation for 
linkage-to-treatment evaluation.3 The intervention was developed 
following stakeholder engagement with the Medical Directors of 
the adult ambulatory care, primary care and hepatology clinics, in 
consultation with the Parkland Chief Executive Officer and Chief 
Medical Officer.
The purpose of this paper was to describe a mixed-method, multi-
modal evaluation of the evidence-based HCV intervention. We have 
previously reported both screening and linkage-to-care significantly 
increased after the HCV intervention was implemented; however, 
over two-thirds of patients still failed to undergo HCV screening 
and one-third with confirmed HCV infection were not linked to 
treatment evaluation, suggesting continued barriers to guideline 
implementation in clinical practice.3 Herein, we sought patient and 
provider experiences to identify ongoing barriers to adoption and 
implementation processes at the system-, provider- and patient-level 
across the HCV screening and treatment evaluation continuum.
2  | METHODS
As previously described, we implemented a multi-modal HCV inter-
vention at Parkland, Dallas County's safety-net integrated health 
system including 12 community-based primary care clinics, outpa-
tient hepatology clinics and a tertiary hospital – all sharing a single 
EHR system.3 Concurrent to this intervention, we conducted an eval-
uation in two phases of data collection: First, we conducted patient 
surveys, focus groups with clinic providers and staff, and structured 
observations of clinic flow and processes (Phase 1). Subsequently, 
we conducted semi-structured interviews with patients and provid-
ers to examine domains and trends of interest identified from initial 
phase data (Phase 2). All participants provided informed consent 
prior to study enrolment.
2.1 | Phase 1 data collection: Patient surveys, 
provider and staff focus groups, and structured 
observation
2.1.1 | Patient surveys
Our survey assessed (a) attitudes towards HCV and people with HCV, 
(b) knowledge about HCV and (c) sociodemographic information. 
Questions were selected because negative attitudes (eg fear or stigma) 
and lack of knowledge could contribute to reluctance to complete 
screening, diagnostic testing or treatment evaluation. The first section 
drew on social discrimination constructs and phrasing from HIV stigma 
instruments, selecting 10 items to assess HCV-related attitudes and 
increased stakeholder buy-in and real-time enhancements to the HCV screening pro-
cess intervention. Systematic data collection at baseline and during practice change 
implementation may facilitate adoption and adaptation to improve HCV screening 
guideline implementation. Findings identified several key opportunities and lessons 
to enhance the impact of practice change interventions to improve HCV screening 
and treatment delivery.
K E Y W O R D S
electronic health records, population health, programme evaluation, qualitative research, 
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feelings.4,5 Although stigma and social discrimination should theoreti-
cally decrease with the shift to cohort-based screening, we included 
these constructs because prior research has indicated stigmatizing 
beliefs are often resistant to change.6,7 In the second section, eight 
questions assessed knowledge about HCV infection, transmission, 
treatment, perceived reasons for testing and sources of information. 
Thirdly, our survey queried patient age, sex, race and ethnicity, lan-
guage and insurance status. Our intention in surveying patients was to 
determine if patient knowledge (about HCV and HCV-related screen-
ing and treatment) and stigma would contribute to continued screen-
ing process failures after implementation of the HCV intervention. We 
believed these constructs could contribute to reluctance to complete 
screening/diagnostic testing as well as impacting patient engagement 
in treatment evaluation. Such findings would inform future interven-
tion design components to improve patient knowledge and/or reduce 
other persistent barriers to HCV screening.
We pre-tested survey items, using established cognitive inter-
view techniques with three English-speaking and three Spanish-
speaking participants, at which point saturation was achieved 
(individuals excluded from findings reported below).8,9 The final 
survey instrument required approximately 10 minutes to complete.
Surveys were administered to patients sampled from three dif-
ferent points along the screening-to-treatment continuum (Figure 1): 
(a) patients with positive HCV antibody who had not completed viral 
load testing (‘antibody reactive’); (b) patients with positive HCV 
viral load who had not completed treatment evaluation (‘HCV con-
firmed’); and (c) patients who completed treatment evaluation at 
the Hepatology Clinic (‘clinic patients’). Exclusion criteria included 
patient refusal, uncontrolled hepatic encephalopathy or other med-
ical conditions precluding survey completion, no phone number on 
file and primary language other than English or Spanish. Antibody-
reactive and HCV-confirmed patients were identified from the EHR-
based patient registry developed as part of the HCV intervention and 
recruited by telephone; clinic patients were also identified through 
the registry but recruited from the Parkland Hepatology Clinic wait-
ing room. Research staff administered surveys by telephone for an-
tibody-reactive and HCV-confirmed patients; clinic patients were 
offered the choice to complete the survey themselves or with the 
assistance of research staff. We aimed to conduct a sample of at 
least 50 surveys in each of the three groups, sufficient to inform 
domains for the second phase of our evaluation.
2.1.2 | Provider and staff focus groups and 
observation
We conducted focus groups at 9 of 12 Parkland primary care clinics. 
We invited providers and clinical staff to participate in a 30-min-
ute open discussion to assess knowledge, attitudes and concerns 
towards HCV screening and linkage to care and interventions to 
promote either step in the continuum. Participants at each clinic var-
ied from 8 to 27, depending on clinic staffing volume and volunteer 
interest. We did not sample from the remaining three clinics due to 
thematic saturation. We then observed a convenience sample of 
providers and staff during nonpatient-contact activities to identify 
potential gaps in the targets of our evaluation, for example commu-
nication or documentation not captured in the EHR. We recruited a 
purposeful sample of key process stakeholders for interviews during 
the observation process, including primary care nurse managers, pri-
mary care providers and HCV Clinic providers and staff.
2.2 | Phase 2 data collection: Semi-
structured interviews
We developed an interview guide to explore themes identified 
from Phase 1, notably barriers to HCV screening process comple-
tion, strategies to enhance screening initiation, follow-up testing 
and linkage to care, and stigma. We interviewed three sets of in-
dividuals 15-18 months after implementation: (a) patients under-
going HCV screening and treatment evaluation, (b) PCPs and staff 
involved in HCV screening and (c) specialty providers and staff at the 
HCV Clinic. All interviews lasted 30-45 minutes and explored the 
following domains: experiences with HCV screening and referral to 
F I G U R E  1   Survey and Interview 
Participant Sampling. Adapted from 
Infectious Diseases Education & 
Assessment, 2018.21
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treatment evaluation processes pre- and post-intervention; commu-
nication among providers, staff and patients; knowledge of HCV and 
treatment; insurance coverage and out-of-pocket costs associated 
with treatment; and HCV-related stigma.
2.2.1 | Patient interviews
As above, we used the EHR patient registry to identify patients 
scheduled for appointments across the screening-treatment contin-
uum, as well as opportunistic recruitment in the Hepatology Clinic 
waiting room. We recruited patients until we reached our target 
enrolment for the three points of the screening-to-treatment con-
tinuum (Figure 1).
2.2.2 | Primary care providers and staff interviews
We interviewed PCPs with the highest and lowest HCV screening 
rates, defined by the proportion of eligible ‘baby boomer’ patients 
for whom HCV screening orders were placed in the prior 6-9 months. 
We also interviewed two nurse manager staff members, selected by 
years of experience with clinic processes, at the recommendation of 
the Director of Nursing.
2.2.3 | Hepatitis C clinic provider and 
staff interviews
In HCV treatment clinics, we interviewed specialty providers and the 
clinic nurse navigator to assess perspectives on potential barriers to 
care.
2.3 | Analysis
For surveys conducted in Phase 1, we used chi-square tests to 
compare levels of knowledge and stigma across the three cohorts 
of patients, using STATA 14 (StataCorp). Focus groups and semi-
structured interviews were transcribed and analysed using NVivo 
9.0 (QSR). Two researchers trained in qualitative methods (RH, 
LQ) developed an initial, deductive codebook corresponding to 
the semi-structured interview guide domains. Researchers jointly 
coded the first six transcripts (‘test set’, 13%), sampling from 
patient and provider transcripts at baseline and post-implemen-
tation, to refine codebook definitions and add emergent codes. 
Researchers double-coded the next 18 transcripts (40%) using the 
refined codebook, meeting weekly to resolve discrepancies. The 
lead analyst (RH) single-coded 14 additional transcripts (31%) until 
reaching thematic saturation at 38 of 45 transcripts (84%). The 
lead analyst then reviewed resulting thematic node reports and 
selected representative quotes and findings for discussion with 
the team.
3  | RESULTS
3.1 | Phase 1: Patient survey findings
We completed 159 surveys (52 antibody-reactive, 51 HCV-
confirmed and 56 clinic patients) and 24 interviews (7 antibody-re-
active, 8 HCV-confirmed and 9 clinic patients), with a diverse sample 
of patients (67% female; 58% Non-Hispanic Black, 29% Hispanic; 
and 17% Spanish-speaking).
We found a significant difference in HCV-related knowledge 
across patient groups, increasing from antibody reactive to HCV 
confirmed to patients who had completed treatment evalua-
tion at the Hepatology Clinic (see Table 1). For example, clinic 
patients were significantly more likely than HCV-confirmed and 
Ab-reactive patients to know that HCV can be present in the ab-
sence of symptoms (91.1% vs 87.3% vs 59.6%; P < .001) or IV drug 
use history (83.9% vs 80.0% vs 59.6%; P = .016), can be fatal if 
untreated (83.9% vs 80.0% vs 51.9%; P < .001) and can now be 
safely treated (69.6% vs 60.0% vs 38.5%; P = .004). However, the 
majority of patients in all three groups recognized that HCV could 
be cured in most patients (78.6% vs 74.5% vs 61.5%, P = .33). Less 
than one-third of patients in each group reported HCV-related 
stigma, including stigmatizing beliefs towards people with HCV or 
any direct experience of perceived stigma. The highest stigma-re-
lated responses included feeling that others talked negatively 
about HCV-infected patients, others not respecting HCV-infected 
patients and self-blame for acquiring HCV infection. Social isola-
tion due to HCV infection was more common in antibody-reactive 
patients than the other two groups (P < .001), being reported in 
over 30% of these patients compared with <10% for the other 
two groups (Table 1).
3.2 | Phase 2: Semi-structured interview findings
3.2.1 | Patient and provider characteristics
We conducted 9 focus groups among 66 providers (physicians, 
nurse practitioners and physician assistants) and 73 staff (nurses 
and social workers) from nine primary care clinics. We then ob-
served nine providers and staff and interviewed 21 providers and 
staff from the same primary care clinics and the HCV treatment 
clinic (Figure 2).
3.2.2 | Provider interviews
Providers expressed some scepticism about the HCV intervention 
prior to its implementation, in light of similar institutional quality im-
provement efforts. However, at the time of our phase 2 evaluation, 
all thought the HCV intervention had a positive impact on the health 
system's ability to screen a higher volume of patients and connect 
them to HCV treatment.
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TA B L E  1   Survey responses to stigma and knowledge items for patients in three cohorts
 









Hepatitis C is a medical condition that can kill you if left untreated <.001
Yes 27 (51.9) 44 (80.0) 47 (83.9)
No 1 (1.9) 2 (3.6) 1 (1.8)
I don't know 24 (46.2) 9 (16.4) 8 (14.3)
People can have Hepatitis C without any signs or symptoms for years <.001
Yes 31 (59.6) 48 (87.3) 51 (91.1)
No 1 (1.9) 1 (1.8) 0 (0.0)
I don't know 20 (38.5) 6 (10.9) 5 (8.9)
People can have Hepatitis C even if they never used IV drugs (drugs that are used with needles) .016
Yes 31 (59.6) 44 (80.0) 47 (83.9)
No 3 (5.8) 4 (7.3) 3 (5.4)
I don't know 18 (34.6) 7 (12.7) 6 (10.7)
Treatment for Hepatitis C is safe and easy to tolerate .004
Yes 20 (38.5) 33 (60.0) 39 (69.6)
No 6 (11.5) 4 (7.3) 8 (14.3)
I don't know 26 (50.0) 18 (32.7) 9 (16.1)
Hepatitis C can be cured in most patients .33
Yes 32 (61.5) 41 (74.5) 44 (78.6)
No 2 (3.8) 1 (1.8) 1 (1.8)
I don't know 18 (34.6) 13 (23.6) 11 (19.6)
Stigma
Were you afraid of being tested for Hepatitis C because of how other people might respond if you tested positive?
Yes a 3 (5.8) 9 (16.4) 11 (19.6) .099
Have you ever been afraid that people would insult you because you have Hepatitis C?
Yes a 16 (30.8) 10 (18.2) 11 (19.6) .238
Have you ever been afraid that people would threaten you because you have Hepatitis C?
Yes a 6 (11.5) 5 (9.1) 2 (3.6) .28
Do you feel that other people talk badly about people with Hepatitis C?
Yes 12 (23.1) 21 (38.2) 21 (37.5) .174
Do you feel that other people don't respect people with Hepatitis C?
Yes 16 (30.8) 17 (30.9) 16 (28.6) .956
Have you ever been left out of social activities because you have Hepatitis C?
Yes a 16 (30.8) 4 (7.3) 3 (5.4) <.001
Do you feel that having Hepatitis C is something to be ashamed of?
Yes 5 (9.6) 9 (16.4) 6 (10.7) .516
Do you think other people should avoid you because you have Hepatitis C?
Yes a 10 (19.2) 3 (5.5) 5 (8.9) .062
Have you ever blamed yourself for having Hepatitis C?
Yes a 16 (30.8) 18 (32.7) 20 (35.7) .859
Do you feel you should be punished for having Hepatitis C?
Yes a 0 (0.0) 1 (1.8) 2 (3.6) .774
aPhrased in the hypothetical for antibody-reactive patients, for example ‘Would you feel….if you had hepatitis C?’ 
Bold entries are significant at p< .05.
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I think it’s just as important as all the other types [of 
screenings]. If we can prevent cirrhosis, liver cancer – 
those are big things. So I think it would definitely be ap-
propriate for it to be a quality metric…That’s the same 
thing as screening mammograms for breast cancer, or 
screening for color cancer. – 
Primary Care Provider
Although nearly all providers felt positively about the BPA, they iden-
tified reasons for continued HCV screening underuse: competing priori-
ties in clinic and desire to group laboratory orders for patient convenience.
It's a great reminder, but sometimes [patients] come with 
so many complaints and they have so many things to ad-
dress, sometimes we may overlook [it]. – 
Primary Care Provider
Providers offered suggestions for improvements including change 
the BPA to appear in multiple EHR views (eg the health maintenance 
page); continue to flag the patient until the screening process includ-
ing confirmatory viral load was completed; and make the BPA message 
more concise (removing information about the USPSTF and CDC’s 
birth cohort recommendation). Most providers responded positively 
about the potential for establishing HCV screening rates as a quality 
metric comparable to existing metrics for cervical and colorectal can-
cer screening; however, others stated that, although the metric was 
positive in theory, they were overwhelmed by the number of existing 
metrics in the context of other competing clinical priorities, especially 
in patients with multiple comorbidities.
Providers responded overwhelmingly positively about the ex-
pansion in hepatology clinic capacity, resulting in fewer referral 
pre-requisite tests, such as HCV genotype, ultrasound, etc and 
shorter patient wait times for HCV treatment evaluation.
In the past year, things are smooth, people are getting 
into hepatitis C clinic. I think it’s pretty easy, we don’t 
have to wait for all these tests. When the results [to 
viral load screening test] are positive, we just refer 
patients, and patients are usually seen, so that’s an 
improvement. – 
Primary Care Provider
Provider education and training by hepatology and infectious 
disease specialists at mandatory institution-wide forums and vol-
untary in-clinic sessions was well-received. However, some pro-
viders still exhibited limited or imprecise HCV-related knowledge 
following these sessions including continued emphasis on screen-
ing high-risk populations over those in the 1945-65 birth cohort, 
being unaware that current HCV treatments are > 90% effective 
and being unaware that patient assistance programmes can make 
treatment available with low or no out-of-pocket cost to underin-
sured patients.
It doesn’t happen often but I do see patients that just 
have positive antibodies with no viral loads being re-
ferred to us. So that’s still some education that needs to 
be done with the PCPs. – 
Hepatology Clinic Provider
3.2.3 | Patient interviews
Patient interviews confirmed patterns observed in our survey data 
with HCV-related knowledge increasing and HCV-related stigma de-
creasing as patients progressed along the HCV screening continuum 
from antibody screening-to-treatment evaluation.
People don’t know… and they act different when they 
know that you’re sick…somebody might find out and 
might not want me to touch them or hold their hands. – 
HCV-Confirmed Patient
I didn’t pass around no needles… so I didn’t really feel bad 
[about having HCV]. I just wanted to get rid of it. I wanted 
it out of my blood. – 
Clinic Patient
Patients reported other barriers to screening and linkage to care 
including lack of clarity regarding out-of-pocket costs, availability of 
DAA treatments to underinsured patients and the high likelihood of 
HCV cure even in difficult-to-treat patient populations.
I know a guy that has it…he was told that pills cost about 
$80,000 or something like that. For that reason he won’t 
try to do anything about it. – 
Antibody-Reactive Patient
F I G U R E  2   Phase 2 data collection
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If they knew you could get cured, they would get tested…
because otherwise, what’s the use? But it’s like, first, to 
know if anything could be done about it, you have to be 
tested. – 
Clinic Patient
Additional exemplar quotes are presented in Table 2.
4  | DISCUSSION
Our evaluation provides insight into guideline implementation in 
large healthcare systems, even as guidelines ostensibly simplify 
recommendations and processes of care. Despite engagement 
with institutional leadership that resulted in fivefold increases 
in screening and treatment capacity,3 clinic providers and pa-
tients identified continued barriers to HCV screening and linkage 
to care in clinical practice. For example, provider interviews re-
vealed ongoing need for education to inform providers about cov-
erage for HCV treatment cost during conversations with patients 
about HCV screening. Patient survey data demonstrated knowl-
edge increases as patients progressed through the screening con-
tinuum and suboptimal knowledge may play a larger role in HCV 
screening than linkage to care and treatment uptake. However, 
interview data suggested a continued need to address persistent 
misconceptions about HCV treatment cost and efficacy in all pa-
tient groups.
Additionally, while our survey data did not indicate statistically 
significant differences across patient cohorts, our patient interview 
data suggest that stigma may still play a role in deterring individuals 
from being screened or treated. Thus, while shifting HCV screening 
from risk-based profiling to a population health approach based on 
birth cohort may decrease disease-associated stigma, some inter-
viewed patients still associated HCV with risk-taking groups, such 
as intravenous drug users. If future screening guidelines recommend 
extending HCV screening to all adults, not just ‘baby boomers’, it is 
possible that the influence of HCV-related stigma may diminish over 
time. Alternatively, it is possible stigma may increase in the future 
with increasing attention being paid to the opioid epidemic and as-
sociated increase in acute HCV infections.
Our evaluation builds on prior studies examining HCV screen-
ing and linkage-to-care interventions. Like other highly successful 
interventions, our intervention effectively integrated screening 
into routine primary care practice10 and utilized a multi-component 
programmatic approach that included clinician and staff education, 
EHR algorithms for eligibility and order entry to serve a hard-to-
reach safety-net population.11 Prior literature suggests that more 
modest designs that emphasize EHR-based tools can also achieve 
remarkable increases in screening and linkage to care.12- However, 
additional evidence-based interventions such as reflex RNA testing 
among patients with positive antibody results, patient navigation15 
and case management16 may further enhance HCV screening and 
linkage to care.
Our empirical findings reinforce a recently published roundtable 
outlining directions for future HCV intervention enhancements.17 
For example, patients need greater assurance that currently avail-
able treatments have dramatically increased the likelihood of being 
cured. Additional support for emotional and social challenges need 
to be provided such as assisting low-income older adults with more 
comorbidities and/or barriers in access to care.16 Similarly, contin-
ued knowledge gaps among patients, particularly those earlier in 
the screening process, highlight an opportunity for better patient 
education when interfacing with primary care providers. It is pos-
sible that lowering barriers to HCV clinic referral may have had the 
unintended consequence of lowering primary care provider educa-
tion of patients, instead deferring this responsibility to HCV clinic 
providers. Thus, our findings offer insights to inform improved per-
formance from diagnosis to cure.
Recent changes in hepatitis C screening and therapy have cre-
ated a paradigm shift in healthcare delivery. Instead of focusing on 
limitations of biomedical barriers, such as treatment eligibility, ef-
forts to enhance care have shifted towards service delivery barri-
ers, including underuse of screening to identify infected individuals. 
This shift requires health systems to optimize screening-to-treat-
ment workflows, which can be particularly challenging for re-
source-limited systems that serve high-prevalence, but complex, 
difficult-to-reach patient populations. Limited clinician time for pre-
ventive care amid more urgent competing clinical demands requires 
additional strategies to facilitate systematic screening. For example, 
outreach invitations have been used in colon cancer and hepatocel-
lular cancer screening but have yet to be evaluated for HCV screen-
ing and linkage to care.18,19 Based on our evaluation findings, we 
are adopting the following new strategies to enhance effectiveness 
of the original intervention: (a) use of mailed outreach strategies to 
identify and better educate at-risk patients who have not undergone 
HCV screening and refer them for screening; (b) posting flyers and 
other print materials emphasizing availability of low- or no-cost HCV 
treatment options, including tolerability and high likelihood of cure; 
and (c) enlisting nurses in primary care clinics to pend orders during 
intake for patients with incomplete HCV screening results (eg anti-
body-reactive result with no confirmatory HCV test). We have initi-
ated additional studies to evaluate effectiveness of these strategies.
Our results must be considered within the context of the lim-
itations of our study design. We evaluated an HCV intervention in 
a single integrated system; however, our multi-modal approach is 
likely to be relevant to other care settings undertaking screening 
and treatment evaluation, especially those seeking to care for under-
served patient populations. In addition, with respect to our findings, 
we acknowledge the association between knowledge and screening 
completion may be driven by reverse causation; in other words, pa-
tients who attended Hepatology Clinic likely received additional ed-
ucation at that time. Our recruitment of physician and staff subjects 
relied on volunteer participation for interviews, and thus results 
may be biased by those who may have had stronger feelings about 
the intervention. Finally, we had a limited number of interview par-
ticipants, although our sample size is typical for qualitative studies 
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TA B L E  2   Exemplar quotes for specific domains
Best practice alert (BPA)
Positive response ‘I see that, okay, it's popping up saying that you need to order [the HCV screening test], so I 
just order it when I order the rest of my labs’
PCP
Nonresponse ‘If I didn't need any other bloodwork, I usually wouldn't [order the HCV screening] because 
most people are going to need blood work sooner or later… every six or even three months…
so just out of patient convenience I do that to group the labs together’
PCP
Provider attitudes & knowledge
Yes to quality 
metric
‘I don't see why it would be a negative thing. As long as we have a place to direct them to, 
[making the HCV screening a quality metric] would be a good thing because otherwise 
they're gonna be walking around with hepatitis C and without receiving treatment’
PCP
No to quality 
metric
‘I can't speak for all physicians, but I do know that a majority of them already feel burdened 
with the requirements of what we have to do in terms of under the health maintenance tab 






‘I remember them saying they have a specialized Hep C Clinic. I noticed it personally too that it 
seems like it's easier to get patients in there and less prerequisites for getting into the clinic. 
I’ve seen it in practice, I think the experience has been quicker and definitely fewer denied 
referrals’
PCP
‘The liver ultrasound before referring the patients – that was one of the hindrances [earlier 
on]. But now they are accepting patients just with a positive hepatitis C result. It's making the 




‘[The COPC forums] are the best time we get to learn updates on everything. We have 
wonderful speakers from different specialties come and update us on guidelines and things 






‘They heard from other people that it was contagious so that's why they might lean away, you 
know, hide…"I don't want to get near them or I might catch it.”’
Clinic patient
‘My nephew – he had hepatitis and cirrhosis of the liver… [My nieces] wouldn't get too close to 
him or hug him or kiss him or anything, even though he was their brother’
Clinic patient
‘People treat people different when they've got viruses, you know, like HIV/AIDS…people 
might not want to sit by you or go out to eat with you, they might not even want to be friends 
with you anymore when they find out about viruses and things they don't understand’.
HCV-confirmed 
patient
Risk behaviour is 
stigmatizing
‘There is a little stigma around it because it's sexually transmitted so people tend to get 
defensive sometimes…They fear having hepatitis because they think it is something they got 
because of something they did’
PCP
‘They acting like you is nasty, you is a drug user’ Ab-reactive patient
‘It's embarrassing to have it…because of the way I contracted it’. I asked, ‘Would it still be 
embarrassing if you had gotten it because you had a blood transfusion or something?’ and he 
said, ‘No, because that [would not have been] my fault’
Clinic patient
Shift focus to 
cohort-based 
screening
‘I’ve said something to people because they was born during the years, “Hey man, have 
you ever had a hepatitis C test?” And I tell them my story. I just happened to see [the 
recommendation for birth cohort testing] on TV. “Man, you need to ask your doctor to check 
that out.” When I see people I talk to them like that…I told probably about 10, 15 people 
that's born around my time’
Clinic patient
‘I can't look for who is at fault…all I want is a solution…because there's nothing you can do 
about it. You're already infected. How can I say, “It was you or her that infected me”? What's 
the point? I put that behind me and I would rather move forward to find a solution for myself’
HCV-confirmed 
patient
Shift focus to cure ‘When it's something you can't get rid of, they don't have a cure for it…it made me feel like it 
was AIDS’
Clinic patient
‘The best thing that's going now is the commercials…seeing there is hope. That's the part. 
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and the consistency of participants’ comments indicated thematic 
saturation.
In conclusion, we identified important opportunities for quality 
improvement to enhance the implementation of a multi-level prac-
tice change initiative to improve HCV screening and linkage to care. 
Patients and providers in our evaluation identified several persistent 
barriers despite our having implemented a multi-component inter-
vention to advance HCV screening and treatment. Clinicians still 
struggled with addressing screening in the context of competing 
clinical concerns and highlighted opportunities for further education 
and/or audit-and-feedback interventions.20 Identifying these bar-
riers informed new strategies to enhance the effectiveness of our 
HCV intervention in the future. Our study highlights the importance 
of systematic stakeholder engagement and iterative intervention re-
finement to optimize adoption and change in clinical practice.
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